Business Description
Lee's Pharmaceutical Holdings Ltd
NAICS : 325412
ISIN : KYG5438W1116
Compare
Compare
Traded in other countries / regions
00950.Hong KongL1PA.GermanyLPCUF.USA IPO Date
2018-10-19Description
Lee's Pharmaceutical Holdings Ltd is a research-driven and market-oriented biopharmaceutical company. Along with its subsidiaries, it develops, manufactures, sells, and markets pharmaceutical products. It focuses on cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company's reportable segments are; Proprietary and generic products which generates key revenue, and Licensed-in products. The Proprietary Products portfolio includes Livaracine, Yallaferon, Slounase, and Nadroparin Calcium Injection. Its Licensed-in Products include Centraxal Plus, Dicoflor, Ferplex, and Natulan among others. Geographically, the company generates a majority of its revenue from the People's Republic of China.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.14 | |||||
| Debt-to-EBITDA | 3.2 | |||||
| Interest Coverage | 1.24 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.59 | |||||
| Beneish M-Score | -2.62 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -4.7 | |||||
| 3-Year EBITDA Growth Rate | -10.5 | |||||
| 3-Year EPS without NRI Growth Rate | -55.4 | |||||
| 3-Year FCF Growth Rate | 29.2 | |||||
| 3-Year Book Growth Rate | -1.8 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.77 | |||||
| 9-Day RSI | 39.4 | |||||
| 14-Day RSI | 42.65 | |||||
| 6-1 Month Momentum % | -8.39 | |||||
| 12-1 Month Momentum % | -10.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | |||||
| Quick Ratio | 0.74 | |||||
| Cash Ratio | 0.31 | |||||
| Days Inventory | 177.85 | |||||
| Days Sales Outstanding | 33.68 | |||||
| Days Payable | 51.8 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.8 | |||||
| Dividend Payout Ratio | 0.15 | |||||
| 3-Year Dividend Growth Rate | -34.8 | |||||
| Forward Dividend Yield % | 3.69 | |||||
| 5-Year Yield-on-Cost % | 0.54 | |||||
| Shareholder Yield % | -3.64 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.49 | |||||
| Operating Margin % | 1.31 | |||||
| Net Margin % | 5.26 | |||||
| FCF Margin % | -0.44 | |||||
| ROE % | 3.3 | |||||
| ROA % | 2.27 | |||||
| ROIC % | 0.58 | |||||
| 3-Year ROIIC % | -37.66 | |||||
| ROC (Joel Greenblatt) % | 17.14 | |||||
| ROCE % | 3.65 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.03 | |||||
| Forward PE Ratio | 7.47 | |||||
| PE Ratio without NRI | 11.03 | |||||
| Shiller PE Ratio | 1.78 | |||||
| PS Ratio | 0.58 | |||||
| PB Ratio | 0.41 | |||||
| Price-to-Tangible-Book | 1.14 | |||||
| Price-to-Operating-Cash-Flow | 5.34 | |||||
| EV-to-EBIT | 9.66 | |||||
| EV-to-EBITDA | 9.66 | |||||
| EV-to-Revenue | 0.62 | |||||
| EV-to-FCF | -142.99 | |||||
| Price-to-Projected-FCF | 0.48 | |||||
| Price-to-Median-PS-Value | 0.19 | |||||
| Price-to-Graham-Number | 0.74 | |||||
| Earnings Yield (Greenblatt) % | 10.35 | |||||
| FCF Yield % | -0.75 | |||||
| Forward Rate of Return (Yacktman) % | -13.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Lee's Pharmaceutical Holdings Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 141.8 | ||
| EPS (TTM) (€) | 0.013 | ||
| Beta | 0.12 | ||
| Volatility % | 32.67 | ||
| 14-Day RSI | 42.65 | ||
| 14-Day ATR (€) | 0.003113 | ||
| 20-Day SMA (€) | 0.1304 | ||
| 12-1 Month Momentum % | -10.88 | ||
| 52-Week Range (€) | 0.12 - 0.169 | ||
| Shares Outstanding (Mil) | 588.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Lee's Pharmaceutical Holdings Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Lee's Pharmaceutical Holdings Ltd Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Lee's Pharmaceutical Holdings Ltd Frequently Asked Questions
What is Lee's Pharmaceutical Holdings Ltd(FRA:L1PA)'s stock price today?
The current price of FRA:L1PA is €0.13. The 52 week high of FRA:L1PA is €0.17 and 52 week low is €0.12.
When is next earnings date of Lee's Pharmaceutical Holdings Ltd(FRA:L1PA)?
The next earnings date of Lee's Pharmaceutical Holdings Ltd(FRA:L1PA) is .
Does Lee's Pharmaceutical Holdings Ltd(FRA:L1PA) pay dividends? If so, how much?
The Dividend Yield %  of Lee's Pharmaceutical Holdings Ltd(FRA:L1PA) is 2.8% (As of Today), Highest Dividend Payout Ratio of Lee's Pharmaceutical Holdings Ltd(FRA:L1PA) was 0.86. The lowest was 0.02. And the median was 0.28. The  Forward Dividend Yield % of Lee's Pharmaceutical Holdings Ltd(FRA:L1PA) is 3.69%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers